The Worsening Renal Perfusion Index predicts the prognoses of heart failure patients treated with sacubitril/valsartan

被引:3
|
作者
Hsu, Wan-Tseng [1 ,2 ,5 ]
Cheng, Yu-Yang [1 ]
Yang, Tsun-Yu [1 ]
Chang, Chao-Kai [1 ]
Lin, Yi-Hsuan [1 ]
Lee, Chii-Ming [3 ]
Huang, Tao-Min [4 ]
机构
[1] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
[3] Fu Jen Catholic Univ, Fu Jen Catholic Univ Hosp, Dept Internal Med, Div Cardiol, New Taipei City, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[5] Natl Taiwan Univ, Sch Pharm, 33 Linsen South Rd,Room 201, Taipei 10050, Taiwan
关键词
WRPSV Index; blood urea nitrogen; echocardiography; hemoglobin; Cox's model; time-dependent covariates; BLOOD UREA NITROGEN; ACTIVATION; MORTALITY; KIDNEY; ANEMIA;
D O I
10.1159/000534095
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Sacubitril/valsartan (S/V) reduces all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF), but it may decline their estimated glomerular filtration rates (eGFR). In addition to eGFR, this clinical study aimed to develop a blood urea nitrogen (BUN)-based index to evaluate the status of renal perfusion and then identify predictors of all-cause death or heart transplant in patients with HFrEF receiving S/V.Methods: From the recruited 291 patients with HFrEF who were prescribed S/V from March 2017 to March 2019, we collected demographic, drug history, laboratory, echocardiographic, and clinical data from one year before S/V initiation until December 2020. Regression analysis was conducted by fitting Cox's models with time-dependent covariates for the survival time and applying the modern stepwise variable selection procedure. The smoothing spline method was used to detect nonlinearity in effect and yield optimal cut-off values for continuous covariates.Results: In the Cox's model, decreased hemoglobin level, decreased mean left ventricular ejection fraction, declined daily dose of S/V, decreased eGFR within 3 months, and increased BUN levels within 1 month and 9 months over time were significantly associated with an increased risk of all-cause death or heart transplant in patients with HFrEF.Conclusions: Adequate maintenance of renal perfusion is crucial for the continuous use of S/V and to avoid worsening renal function in patients with HFrEF. We defined the maximum increase in BUN levels within a specified period as the Worsening Renal Perfusion Index (WRPSV Index) to capture the prognostic effect of renal hypoperfusion in patients with HFrEF.
引用
收藏
页码:310 / 323
页数:14
相关论文
共 50 条
  • [31] Sacubitril/Valsartan (Entresto) for Heart Failure
    Abramowicz, Mark
    Zuccotti, Gianna
    Pflomm, Jean-Marie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (07): : 722 - 723
  • [32] Sacubitril/Valsartan (Entresto) for Heart Failure
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1474): : 107 - 109
  • [33] Sacubitril/valsartan in heart failure and end-stage renal insufficiency
    Heyse, Alex
    Manhaeghe, Lynn
    Mahieu, Elien
    Vanfraechem, Celine
    Van Durme, Frederik
    ESC HEART FAILURE, 2019, 6 (06): : 1331 - 1333
  • [34] The Effect of Sacubitril/Valsartan on Selvester Score in Heart Failure Patients
    Ulusan, Sebahat
    Peynirci, Ahmet
    Ozdil, Omer
    Sahin, Adnan
    Kuyumcu, Mevlut Serdar
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 142 : S9 - S10
  • [35] Perceived Barriers to Sacubitril/Valsartan Use in Patients with Heart Failure
    Shah, Kevin S.
    Ziaeian, Boback
    Mody, Freny V.
    Nsair, Ali
    Fonarow, Gregg C.
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (08) : S99 - S99
  • [36] Reverse myocardial remodeling and reduction of inflammatory markers in patients with heart failure treated with sacubitril/valsartan
    Porcile, Rafael
    Zuniga Infantas, Maria T.
    Levin, Ricardo
    Perez Baztarrica, Gabriel
    Salvaggio, Flavio
    Botbol, Livio A.
    INSUFICIENCIA CARDIACA, 2018, 13 (03) : 104 - 109
  • [37] Effectiveness of sacubitril-valsartan in cancer patients with heart failure
    Martin-Garcia, Ana
    Lopez-Fernandez, Teresa
    Mitroi, Cristina
    Chaparro-Munoz, Marinela
    Moliner, Pedro
    Martin-Garcia, Agustin C.
    Martinez-Monzonis, Amparo
    Castro, Antonio
    Lopez-Sendon, Jose L.
    Sanchez, Pedro L.
    ESC HEART FAILURE, 2020, 7 (02): : 763 - 767
  • [38] Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure
    Ezekowitz, Justin A.
    JAMA CARDIOLOGY, 2017, 2 (01) : 86 - 87
  • [39] An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands
    van der Pol, Simon
    Degener, Fabian
    Postma, Maarten J.
    Vemer, Pepijn
    VALUE IN HEALTH, 2017, 20 (03) : 388 - 396
  • [40] The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
    Zhang, Rui
    Sun, Xiaotong
    Li, Ya
    He, Wenzheng
    Zhu, Hongguang
    Liu, Baoshan
    Zhang, Aiyuan
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022, 27